N/A
N=117
Intraoperative Neuromuscular Blockade and Postoperative Atelectasis
Thoracic Surgery · One-lung Ventilation
Bottom Line
View on ClinicalTrials.gov: NCT03503565 ↗Enrolled (actual)
117
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: Atelectasis Area on Chest CT — 1.32; 1.41 percentage of atelectasis volume
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- intraoperative neuromuscular blockade (Procedure)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- All
- Sponsor
- Kyung Hee University Hospital at Gangdong
- Primary completion
- May 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Atelectasis Area on Chest CT |
1.32; 1.41 | — |
| SECONDARY Number of Patients Defined as Acute Respiratory Distress Syndrome |
— | — |
| SECONDARY Number of Patients Defined as Pneumonia |
— | — |
| SECONDARY Number of Patients Showing Pleural Effusion |
— | — |
| SECONDARY Number of Patients Showing Postoperative Desaturation |
— | — |
| SECONDARY Number of Patients Requiring Postoperative Re-intubation |
— | — |
| SECONDARY Intraoperative Lung Compliance (ml/cmH2O) |
— | — |
| SECONDARY Patient Demographic Data |
— | — |
Summary
During one-lung ventilation in thoracic surgery, the intensity of neuromuscular blockade may change the compliance and resistance of ventilated lung, thereby affecting postoperative atelectasis. The present study investigated the effect of the intensity of intraoperative neuromuscular blockade on the postoperative atelectasis using chest computerized tomography in patients receiving thoracic surgery requiring one-lung ventilation.
Eligibility Criteria
Inclusion Criteria
- Patients receiving scheduled unilateral lung lobectomy.
- Patients age ≥19
- Patients of American Society of Anesthesiologist Physical Status 1 or 2
Exclusion Criteria
- Patients receiving bilateral lung lobectomy
- Patients BMI > 35.0 or < 18.5 kg/m2
- Patients of contraindicated to epidural patients controlled analgesia
- Patients with neuromuscular disease (i.e. myasthenia gravis)
- Patients with major burn (more than 3rd degrees)
- Patients with compromised cardiopulmonary function.
Data sourced from ClinicalTrials.gov (NCT03503565). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.